Advaxis to Present at Upcoming March Conferences

• Date and Time: Thursday, March 15, 2018 at 9:30am ET
• Venue: Loews Miami Beach Hotel, Miami, FL
• Presenter: Anthony Lombardo, Interim Chief Executive Officer
• Presentation: Company overview

25^th Annual Future Leaders in the Biotech Industry Conference

• Date and Time: Friday, March 23^rd at 3:00pm ET
• Venue: Millennium Broadway Hotel & Conference Center, New York, NY
• Presenter: Robert Petit, Ph.D., EVP and Chief Scientific Officer
• Presentation: Company overview

About Advaxis, Inc.

Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains integrate multiple functions into a single immunotherapy, and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and near-clinical development: HPV-associated cancers, individualized neoantigen immunotherapy, cancer-specific hotspot mutation immunotherapies and prostate cancer.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180313005417/en/